It has also been proposed that this same mechanism that lends PD-1 inhibitors’ efficacy in treatment of cancer may also predispose patients to neuropathy through autoreactivity against shared neural antigens which are both produced by tumor cells and present in peripheral nerves [15,16]. This evidence concerns the gene PDCD1 and neoplasm.